CRISPR and CAS Genes Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 15.67 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
CRISPR and CAS Genes Market Analysis
The CRISPR and CRISPR-associated (Cas) genes market is expected to register a CAGR of 15.67% over the forecast period.
- The COVID-19 pandemic had a significant impact on the market due to an increase in demand for COVID-19 diagnostic tests since the CRISPR-Cas-based methods diagnose the SARS-CoV-2 infections within an hour. As per the April 2022 update from Duke Health, a study conducted by the researchers demonstrated that CRISPR technology represents a unique strategy for controlling SARS-CoV-2 infection and should be pursued as a potential approach for treating COVID.
- The CRISPR/Cas13 delivered intravenously through a lipid nanoparticle diminished CTSL in the animals' lungs, effectively and safely blocking the SARS-CoV-2 virus from entering cells and infecting the host. Thus, studies such as these are expected to have a positive effect on the market for CRISPR and CRISPR-associated (Cas) Genes. Since the restrictions of COVID-19 is relaxed, the market is anticipated to witness growth in the coming years due to the increase in research activities involving CRISPR and CRISPR-associated (Cas) Genes.
- Factors attributing to the growth of the market include increasing investment by biotechnology companies for novel therapeutics, a rise in genomics research and development activities, and a high burden of cancer and other diseases. For instance, in January 2021, Pfizer Inc. invested a total of USD 120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer invested up to USD 500 million in biotechnology companies, providing funding and access to Pfizer's scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer. Hence, such investment by the key players is expected to increase the development of CRISPR and CRISPR-associated (Cas) genes and thereby drive market growth over the forecast period.
- Furthermore, the rise in genomics research and development activities that demonstrate the efficiency of CRISPR technologies is likely to boost market growth over the forecast period. For instance, in May 2022, Vertex and CRISPR Therapeutics presented new clinical data on investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for severe hemoglobinopathies at the annual European Hematology Association Virtual Congress. CTX001 is being investigated in two ongoing clinical trials as a potential one-time curative therapy for patients suffering from TDT and severe SCD.
- Moreover, a high burden of cancer and other diseases is boosting market growth since CRISPR technology has been found to help identify the mutations in several cancers. For instance, as per the American Cancer Society, the estimated number of people diagnosed with cancer in 2022 was 1.9 million in the United States.
- Additionally, in the article published in November 2022 in Nature Journal, researchers can use CRISPR gene editing to change immune cells so that they will recognize altered proteins unique to a person's tumors. Then, those cells can be safely released into the body to locate and eliminate their target. Hence, such personalized treatment options provided by the CRISPR technologies for chronic disease like cancer is expected to drive the market growth over the forecast period.
- Hence, due to the rising investment by biotechnology companies for novel therapeutics and the increase in genomics research and development activities, the market studied is anticipated to witness growth over the forecast period. However, off-target effects associated with the implementation of CRISPR and high cost and ethical concerns associated with CRISPR technology are expected to restrain the market growth over the forecast period.
CRISPR and CAS Genes Market Trends
Genome Engineering Segment is Anticipated to Witness a Growth in the Market Over the Forecast Period
- The market's genome engineering segment is likely to grow due to the increase in genomics research and development activities and funding. The CRISPR genome engineering system uses a nuclease, CRISPR-associated protein 9 (Cas9) that complexes with small guide RNAs (gRNAs) to cleave DNA in a sequence-specific manner upstream of the protospacer adjacent motif (PAM) in any genomic location.
- As per an article published in May 2022 in Frontiers, the introduction of specific mutations into mammalian cells to produce loss-of-function phenotypes is made simple by CRISPR technology. With the successful application of genome-wide CRISPR screening to discover host characteristics that limit viral infections, CRISPR became a potent tool for investigating the functional genomics of virus-host interactions.
- Moreover, various companies and academic and research institutions are using genome engineering techniques for the development of new therapies and treatments. Many researchers received funding to develop and establish genome engineering-related research, expected to drive segment growth over the forecast period. For instance, in December 2022, an assistant professor of biomedical engineering and computer science received USD 1.9 million in awards from the National Institutes of Health for genome sequencing research. The researcher also received USD 120,000 from Complete Genomics, a company that focuses on human genome sequencing.
- Furthermore, genomic engineering studies to understand cancer cells and their therapies gained a lot of attention, and that is expected to be a growth factor for the segment growth. For instance, as per the article published in October 2021 in BMC Journal, CRISPR/Cas9 can be utilized in the field of cancer research to modify genomes for the investigation of the mechanisms of carcinogenesis and development because genomic alterations in tumor cells cause cancer.
- Hence, due to the rise in research funding in genomic studies and the increase in research conducted to represent the efficacy of CRISPR in genomics, the segment studied is anticipated to witness growth over the forecast period.
North America is Anticipated to Hold a Significant Growth in the CRISPR and CRISPR-associated (Cas) Genes Market Over the Forecast Period
- North America is expected to hold a significant market share in the CRISPR and CRISPR-Associated (Cas) genes market throughout the forecast period due to factors such as the high burden of cancer and other diseases, increasing genomics research and development activities and funding, and established healthcare infrastructure. For instance, in November 2021, CRISPR Therapeutics and ViaCyte publicized that Canada's medical agency Health Canada approved their clinical trial application for VCTX210, a CRISPR-edited stem cell therapy designed to treat type 1 diabetes. This is a milestone in medicine as it marks the first-ever gene-edited therapy for diabetes to approach the clinic.
- Furthermore, beneficial government initiatives and increased research partnerships are some drivers expected to increase market growth. Over the years, companies have collaborated with their peers to tap into certain niche segments of the CRISPR and CRISPR-Associated (Cas) genes market. For instance, in September 2022, the United States publicized new investments and resources to advance the National Biotechnology and Biomanufacturing initiative. As a part of this initiative, the Department of Health and Human Services is likely to invest USD 40 million to expand the role of biomanufacturing.
- Such rising funding activities by the government are expected to contribute to the market growth in this region. Thus, due to the rise in clinical studies associated with CRISPR and the increase in research funding, North America is anticipated to hold a significant market share over the forecast period.
CRISPR and CAS Genes Industry Overview
The CRISPR and CRISPR-associated (Cas) genes market is consolidated and consists of a few major players. Additionally, the key players have been involved in various strategic alliances, such as acquisitions, collaborations, and financing, along with the launch of advanced products to secure their position in the global market. Some of the key market players are OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio Inc, PerkinElmer Inc. (Horizon Discovery Ltd.), Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR THERAPEUTICS, Editas Medicine, and Mirus Bio LLC.
CRISPR and CAS Genes Market Leaders
-
OriGene Technologies, Inc.
-
Thermo Fisher Scientific
-
Takara Bio Inc
-
Addgene
-
PerkinElmer Inc. (Horizon Discovery Ltd.)
*Disclaimer: Major Players sorted in no particular order
CRISPR and CAS Genes Market News
- December 2022: A researcher from the University of California sponsored a clinical trial under the title "Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease" to evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR_SCD001 Drug Product).
- November 2022: Massachusetts Institute of Technology researchers designed a new CRISPR-based tool that inserts large DNA sequences at desired sites in cells, known as PASTE the technique holds the potential for treating a variety of diseases caused by faulty genes.
CRISPR and CAS Genes Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Investment by Biotechnology Companies for Novel Therapeutics
- 4.2.2 Increasing Genomics Research and Development Activities and Funding
- 4.2.3 High Burden of Cancer and Other Diseases
-
4.3 Market Restraints
- 4.3.1 Off-target Effects Associated with the Implementation of CRISPR
- 4.3.2 High Cost and Ethical Concerns Associated with CRISPR Technology
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Product
- 5.1.1 Vector-based Cas
- 5.1.2 DNA-free Cas
-
5.2 By Application
- 5.2.1 Genome Engineering
- 5.2.2 Disease Models
- 5.2.3 Functional Genomics
- 5.2.4 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 OriGene Technologies, Inc.
- 6.1.2 Thermo Fisher Scientific
- 6.1.3 Takara Bio Inc
- 6.1.4 PerkinElmer Inc. (Horizon Discovery Ltd.)
- 6.1.5 Addgene
- 6.1.6 Merck KGaA
- 6.1.7 Caribou Biosciences, Inc.
- 6.1.8 CRISPR THERAPEUTICS
- 6.1.9 Editas Medicine
- 6.1.10 Mirus Bio LLC
- 6.1.11 Intellia Therpeutics
- 6.1.12 Sangamo Therapeutics
- 6.1.13 Inscripta, Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCRISPR and CAS Genes Industry Segmentation
As per the scope of the report, clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) Genes market, CRISPR-Cas9, which is an acronym for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 is a microbial adaptive immune system against viruses and plasmids, that gives scientists the ability to change an organism's DNA (genome editing).
The CRISPR and CRISPR-associated (Cas) genes market is segmented by product (vector-based cas and DNA-free cas), application (genome engineering, disease models, functional genomics, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Product | Vector-based Cas | |
| DNA-free Cas | ||
| By Application | Genome Engineering | |
| Disease Models | ||
| Functional Genomics | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
CRISPR and CAS Genes Market Research FAQs
What is the current CRISPR And CRISPR-associated (Cas) Genes Market size?
The CRISPR And CRISPR-associated (Cas) Genes Market is projected to register a CAGR of 15.67% during the forecast period (2024-2029)
Who are the key players in CRISPR And CRISPR-associated (Cas) Genes Market?
OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio Inc, Addgene and PerkinElmer Inc. (Horizon Discovery Ltd.) are the major companies operating in the CRISPR And CRISPR-associated (Cas) Genes Market.
Which is the fastest growing region in CRISPR And CRISPR-associated (Cas) Genes Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in CRISPR And CRISPR-associated (Cas) Genes Market?
In 2024, the North America accounts for the largest market share in CRISPR And CRISPR-associated (Cas) Genes Market.
What years does this CRISPR And CRISPR-associated (Cas) Genes Market cover?
The report covers the CRISPR And CRISPR-associated (Cas) Genes Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the CRISPR And CRISPR-associated (Cas) Genes Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
CRISPR and CAS Genes Industry Report
Statistics for the 2024 CRISPR and CAS Genes market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. CRISPR and CAS Genes analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
